

The Purest OTC & VMS global player¹.

0.5b

Consumers served worldwide².

€4.6b

Net Sales³.

#3

OTC & VMS player globally¹.

Let the numbers talk.

~11k

Employees.

13

Best-in-class manufacturing sites globally.

38

Countries with direct operations.

4

Specialized science & innovation development centers.

~100

Clinical studies in the last 10 years.

~2M

Interactions with healthcare professionals globally.

+200

Scientific publications in last 3 years.

1st

Global consumer healthcare company to achieve B Corp Certification.

15 focus brands within top 3 positions¹.

Global brands.



3rd Allergy.



1st Probiotics.



1st France, Systemic analgesics.



1st Europe, Mineral - magnesium.



1st Japan, Systemic analgesics.



2nd Laxatives.



1st Liver & bile. Excl TCM.



1st US, CoQ10.



3rd US, Topical analgesics.⁴



1st Australia & South Korea, Multi vitamins.



1st Antispasmodic & IBS.



3rd Cough. Excl TCM.



2nd LATAM, Multi vitamins.



1st Brazil, Systemic analgesics.



4th Brazil, Systemic analgesics.

Our equation for a healthier future.

Health³
Planet x People x Business.

PILLAR.

REPORTING THEME.

STRATEGIC PRIORITY.

Healthy Planet.

Climate Action.
Nature & Resources.

Net-Zero.
Reduce absolute emissions on Scopes 1, 2, and 3 by 58.8% by 2034 and 90% by 2050.

Healthy People.

Thriving Teams & Partners.
Empowering Self-Care.

Health Literacy.
Improve the health literacy of 50 million people annually.

Healthy Business.

Responsibility & Ethics.
Resilient Value Chain.

B Corp.
Achieve B Corp 5-year requirements by 2031.

OTC: Over-the-counter. VMS: Vitamins, Minerals & Supplements. TCM: Traditional Chinese medicine. (1) Group data and analysis on the basis of market studies conducted by third parties, including the Nicholas Hall DB6 2026™; (2) Internal Opella penetration study 2023; (3) Based on Opella audited combined financial statements for the year ended December 31, 2025. (4) US local market data FY 2025.